In the second quarter of 2009, ZymoGenetics’ net loss improved to $27 million, or $0.39 per share, from $37.4 million, or $0.54 per share, for the second quarter of 2008. Revenues for the second quarter of 2009 were $22.6 million, as compared to $12.6 million for the prior year quarter.
The company’s net loss declined to $26.9 million, as compared to previous year’s $37.3 million. The basic and diluted net loss per share was $0.39, compared to $0.54.
For the six month ended period, the company recorded total revenues of $47.4 million, compared to previous year’s period. Net loss also decreased to $45.1 million from $78.2 million. ZymoGenetics also recorded basic and diluted net loss per share of $0.65, compared to $1.14.
Douglas Williams, chief executive officer of ZymoGenetics, said: “We made substantial progress during the quarter toward our goals for the year. The development of PEG-Interferon lambda is proceeding according to plan, with the recent completion of Phase 1b enrollment and preparations underway for Phase 2 initiation later this year. RECOTHROM sales trends are on track to meet our guidance for the year. The company’s financial outlook has been improved through the corporate restructuring announced in April. We’re focused on continuing to build on these trends over the remainder of the year.”